<DOC>
	<DOCNO>NCT00523848</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , doxorubicin hydrochloride liposome , work different way stop growth cancer cell , either kill cell stop dividing . Thalidomide may stop growth multiple myeloma block blood flow cancer . Giving bortezomib together doxorubicin hydrochloride liposome thalidomide may kill cancer cell . PURPOSE : This phase II trial study well give bortezomib together doxorubicin hydrochloride liposome thalidomide work first-line therapy treat patient previously untreated multiple myeloma .</brief_summary>
	<brief_title>Bortezomib , Doxorubicin Hydrochloride Liposome , Thalidomide First-line Therapy Treating Patients With Previously Untreated Stage I , II , III Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine overall response rate ( complete response partial response ) patient previously untreated stage I , II , III multiple myeloma . Secondary - To evaluate complete response rate patient treat regimen . - To determine time disease progression start therapy patient treat regimen . OUTLINE : Patients receive low-dose oral thalidomide day day 1-28 , bortezomib IV day 1 , 4 , 15 , 18 , doxorubicin hydrochloride liposome IV 60-90 minute day 1 15 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Patients residual disease continue show response completion 6 course may receive 2 additional course total 8 course . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage I , II , III multiple myeloma require therapy No prior systemic therapy multiple myeloma Patients receive steroid radiotherapy cord compression spinal cord disease eligible study Patients receive 1 prior course antimyeloma therapy may enrol investigator 's discretion provide disease progression note PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status 60100 % Platelet count ≥ 75,000 cells/mm^3 ( &lt; 75,000 cells/mm^3 secondary extensive bone marrow disease allow PI 's discretion appropriate transfusion support ) ANC ≥ 1,000 cells/mm^3 Hemoglobin ≥ 8.0 g/dL ( &lt; 8 g/dL secondary extensive bone marrow disease allow PI 's discretion appropriate transfusion support ) Creatinine clearance &gt; 20 mL/min AST ALT ≤ 2 time upper limit normal ( ULN ) OR ≤ 3 time ULN ( presence liver metastasis ) Alkaline phosphatase ≤ 2 time ULN OR ≤ 3 time ULN ( presence liver metastasis ) Total bilirubin ≤ 2 time ULN OR ≤ 3 time ULN ( presence liver metastasis ) Ejection fraction ≥ 50 % MUGA 2D echocardiogram Negative pregnancy test Fertile patient must use least 1 highly effective 1 additional effective contraception method 4 week prior , , 3 month completion study therapy HIVnegative Must sufficient mental capacity understand explanation study provide inform consent Willingness ability comply FDAmandated S.T.E.P.S . program Exclusion criterion : Pregnant lactate Active , serious infection uncontrolled antibiotic Any medical condition reason , investigator 's opinion , make patient unsuitable participate clinical trial History hypersensitivity reaction attribute conventional formulation doxorubicin hydrochloride component doxorubicin hydrochloride liposome bortezomib , boron , mannitol Any follow condition : History uncontrolled New York Heart Association class IIIV heart disease clinical evidence congestive heart failure Myocardial infarction within past 6 month Uncontrolled angina Severe uncontrolled ventricular arrhythmia , ECG evidence acute ischemia , active conduction system abnormalities Peripheral neuropathy ≥ grade 2 PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>